{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T15:28:27Z","timestamp":1771169307014,"version":"3.50.1"},"reference-count":11,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oral and scalp lesions of pemphigus heal slower than lesions at other sites, leading to an extended duration of oral corticosteroids, thereby contributing to adverse effects. Intravenous rituximab (IV\u2010RTX) has proven to be invaluable in pemphigus management. However, there is limited literature on the use of intralesional rituximab (IL\u2010RTX) in recalcitrant mucocutaneous pemphigus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>\n                      In this retrospective observational study, diagnosed cases of pemphigus with refractory oral and\/or scalp lesions who had received IL\u2010RTX were included. IL\u2010RTX was administered at a dose of 5\u2009mg\/cm\n                      <jats:sup>2<\/jats:sup>\n                      (10\u2009mg\/mL), two doses fortnightly with or without concomitant IV\u2010RTX. Response was assessed by mucosal\/scalp Pemphigus disease area index (PDAI) and anti\u2010desmoglein antibody (anti\u2010DSG) levels at baseline and 6\u2009months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty\u2010three patients (M:F\u2009=\u20091:0.94) who met the inclusion criteria were included. The mean age was 45.15\u2009years. Twenty\u2010seven patients (82%) received concurrent IV\u2010RTX, and six patients (18%) received only IL\u2010RTX. At the end of 6\u2009months, a statistically significant decrease was seen in mucosal\/scalp PDAI and anti\u2010DSG1 and anti\u2010DSG3 levels in patients who received only IL\u2010RTX as well as patients who received concomitant IV\u2010RTX and IL\u2010RTX. The percentage of patients on concomitant corticosteroids decreased from 88% at baseline to 48% at 6\u2009months. Pain was the only adverse effect, seen in six patients (18%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>IL\u2010RTX is a cost\u2010effective and safe modality for the treatment of localized recalcitrant lesions of pemphigus. It can be considered more beneficial than increasing the dosage of systemic therapy. Intravenous and intralesional rituximab can be used concurrently and synergistically for recalcitrant oral and scalp lesions of pemphigus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.18001","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:45:42Z","timestamp":1754045142000},"page":"119-123","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intralesional Rituximab in Recalcitrant Oral and Scalp Lesions of Pemphigus: A Retrospective Study"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5873-2242","authenticated-orcid":false,"given":"Vishalakshi","family":"Viswanath","sequence":"first","affiliation":[{"name":"Rajiv Gandhi Medical College &amp; Chhatrapati Shivaji Maharaj Hospital  Thane Maharashtra India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1367-9410","authenticated-orcid":false,"given":"Isha Kiran","family":"Kane","sequence":"additional","affiliation":[{"name":"Rajiv Gandhi Medical College &amp; Chhatrapati Shivaji Maharaj Hospital  Thane Maharashtra India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9030-1629","authenticated-orcid":false,"given":"Nupur Mukesh","family":"Sanklecha","sequence":"additional","affiliation":[{"name":"Rajiv Gandhi Medical College &amp; Chhatrapati Shivaji Maharaj Hospital  Thane Maharashtra India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9258-432X","authenticated-orcid":false,"given":"Pradnya Rushikesh","family":"Joshi","sequence":"additional","affiliation":[{"name":"Rajiv Gandhi Medical College &amp; Chhatrapati Shivaji Maharaj Hospital  Thane Maharashtra India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119709268.rook050"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(05)66829\u20108"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.3674"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/615439"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1874915"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15528"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13154"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14407"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.04.031"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cap.10033"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.16892"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.18001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:19:43Z","timestamp":1766049583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.18001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/ijd.18001"],"URL":"https:\/\/doi.org\/10.1111\/ijd.18001","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2025-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}